Concepedia

Alison Turner

AT

Statistics

Publications

34

Citations

3K

H-Index

25

Active since

1982

Affiliations

UCB Pharma (United Kingdom)(Current)

University of Oxford

Jenner Institute

Vector Oncology (United States)

University College London

Alison Turner is an author at UCB Pharma (United Kingdom) specializing in immunology, pharmacy, and life sciences.

ORCID

Publications per year

1982–2022

34

Publications

34

Correction: Corrigendum: The blood-stage malaria antigen PfRH5 is susceptible to vaccine-inducible cross-strain neutralizing antibody

Alexander D. Douglas, Andrew R. Williams, Joseph J. Illingworth et al. · Nature Communications · 2013 · 926 citations · Full text

, , +14

The blood-stage malaria antigen PfRH5 is susceptible to vaccine-inducible cross-strain neutralizing antibody

Alexander D. Douglas, Andrew R. Williams, Joseph J. Illingworth et al. · Nature Communications · 2011 · 292 citations · Full text

, , +14

A single amino acid substitution abolishes the heterogeneity of chimeric mouse/human (IgG4) antibody

Sarojani Angal, David J. King, Mark Bodmer et al. · Molecular Immunology · 1993 · 243 citations

, , +13

A PfRH5-Based Vaccine Is Efficacious against Heterologous Strain Blood-Stage Plasmodium falciparum Infection in Aotus Monkeys

Alexander D. Douglas, G. Christian Baldeviano, Carmen M. Lucas et al. · Cell Host & Microbe · 2015 · 238 citations · Full text

, , +17

Improved tumor targeting with chemically cross-linked recombinant antibody fragments.

DJ King, Alison Turner, AP Farnsworth et al. · PubMed · 1994 · 126 citations

, , +17

1–5 of 34